174 related articles for article (PubMed ID: 35677424)
1. The Antithrombotic Effect of Recombinant Neorudin on Thrombi.
Liu YB; Zhang L; Zhou XC; Zhou Y; Liu Y; Zheng C; Xu X; Geng PP; Hao CH; Zhao ZY; Wu CT; Jin JD
Drug Des Devel Ther; 2022; 16():1667-1678. PubMed ID: 35677424
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory role of recombinant neorudin on canine coronary artery thrombosis.
Liu YB; Zhou XC; Liu Y; Zhang L; Zhou Y; Xu X; Zheng C; Zhao ZY; Wu CT; Jin JD
Pharmacol Res Perspect; 2022 Jun; 10(3):e00956. PubMed ID: 35505637
[TBL] [Abstract][Full Text] [Related]
3. Recombinant Neorudin for the Prevention of Deep-Vein Thrombosis After Spinal-Cord Injury.
Liu YB; Liu Y; Zhang L; Zhou XC; Ren BY; Zheng C; Hao CH; Wang WT; Xia X; Zhou GQ; Wu CT; Jin JD
Drug Des Devel Ther; 2023; 17():2523-2535. PubMed ID: 37641688
[TBL] [Abstract][Full Text] [Related]
4. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
[TBL] [Abstract][Full Text] [Related]
5. Predicting the metabolic characteristics of neorudin, a novel anticoagulant fusion protein, in patients with deep vein thrombosis.
Dong X; Meng Z; Gu R; Zhu X; Gan H; Jin J; Liu J; Dou G
Thromb Res; 2020 Oct; 194():121-134. PubMed ID: 32788104
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic action of recombinant hirudin in a venous thrombosis model.
Raake W; Klauser RJ; Elling H; Zeiller P
Haemostasis; 1991; 21 Suppl 1():127-32. PubMed ID: 1654293
[TBL] [Abstract][Full Text] [Related]
7. Evaluating prodrug characteristics of a novel anticoagulant fusion protein neorudin, a prodrug targeting release of hirudin variant 2-Lys47 at the thrombosis site, by means of in vitro pharmacokinetics.
Dong X; Gu R; Zhu X; Gan H; Liu J; Jin J; Meng Z; Dou G
Eur J Pharm Sci; 2018 Aug; 121():166-177. PubMed ID: 29802897
[TBL] [Abstract][Full Text] [Related]
8. A factor XIa-activatable hirudin-albumin fusion protein reduces thrombosis in mice without promoting blood loss.
Sheffield WP; Eltringham-Smith LJ; Bhakta V
BMC Biotechnol; 2018 Apr; 18(1):21. PubMed ID: 29621998
[TBL] [Abstract][Full Text] [Related]
9. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH
Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the antithrombotic effect of the new recombinant hirudin HBW 023 and heparin in small arteries and veins.
Zhang B; Wieslander JB
Microsurgery; 1996; 17(2):89-96. PubMed ID: 8914063
[TBL] [Abstract][Full Text] [Related]
11. The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal models.
Bacher P; Walenga JM; Iqbal O; Bajusz S; Breddin K; Fareed J
Thromb Res; 1993 Aug; 71(4):251-63. PubMed ID: 8236155
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of three recombinant hirudins with heparin in an experimental venous thrombosis model.
Doutremepuich C; Lalanne MC; Doutremepuich F; Walenga J; Fareed J; Breddin HK
Haemostasis; 1991; 21 Suppl 1():99-106. PubMed ID: 1894201
[TBL] [Abstract][Full Text] [Related]
13. Construction and functional evaluation of hirudin derivatives with low bleeding risk.
Zhang C; Yu A; Yuan B; Dong C; Yu H; Wang L; Wu C
Thromb Haemost; 2008 Feb; 99(2):324-30. PubMed ID: 18278181
[TBL] [Abstract][Full Text] [Related]
14. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
Morishima Y; Honda Y; Kamisato C; Shibano T
Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
[TBL] [Abstract][Full Text] [Related]
15. Antithrombotic activity of recombinant hirudin in the rat: a comparative study with heparin.
Doutremepuich C; Deharo E; Guyot M; Lalanne MC; Walenga J; Fareed J
Thromb Res; 1989 Jun; 54(5):435-45. PubMed ID: 2772867
[TBL] [Abstract][Full Text] [Related]
16. Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis.
Biemond BJ; Friederich PW; Levi M; Vlasuk GP; Büller HR; ten Cate JW
Circulation; 1996 Jan; 93(1):153-60. PubMed ID: 8616922
[TBL] [Abstract][Full Text] [Related]
17. Effects of different hirudins and combinations of low doses of hirudin, heparin and acetylsalicylic acid in a rat microcirculatory thrombosis model.
Krupinski K; Breddin HK
Haemostasis; 1991; 21 Suppl 1():88-92. PubMed ID: 1894199
[TBL] [Abstract][Full Text] [Related]
18. Antithrombotic and haemorrhagic effects of the naturally occurring thrombin inhibitor hirudin.
Kaiser B; Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):41-6. PubMed ID: 2459030
[TBL] [Abstract][Full Text] [Related]
19. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits.
Agnelli G; Pascucci C; Cosmi B; Nenci GG
Thromb Haemost; 1990 Apr; 63(2):204-7. PubMed ID: 2363121
[TBL] [Abstract][Full Text] [Related]
20. Experimental studies on a recombinant hirudin, CGP 39393.
Gray E; Watton J; Cesmeli S; Barrowcliffe TW; Thomas DP
Thromb Haemost; 1991 Apr; 65(4):355-9. PubMed ID: 2057916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
